Preliminary results from 86 patients enrolled in the Phase 2 pivotal iMMagine-1 study of anito-cel demonstrated 97% ORR and 62% CR/sCR at a median follow-up of 9.5 months No delayed neurotoxicities have been observed to date with anito-cel, including no Parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome in more than 150 patients dosed across the Phase 1 and iMMagine-1 studies 30.2-month median... Read More

Recently released ASH abstracts for the company’s Phase 1 and iMMagine-1 studies investigating anito-cel in relapsed or refractory multiple myeloma patients continue to demonstrate durability and a manageable safety profile 30.2-month median progression-free survival with a median follow-up of 38.1 months in the Phase 1 study of anito-cel; median overall survival not reached Preliminary results from 58 patients enrolled in... Read More

30.2-month median progression-free survival with a median follow-up of 38.1 months in the Phase 1 study of anito-cel; median overall survival not reached Preliminary results from 58 patients enrolled in the Phase 2 pivotal iMMagine-1 study demonstrated 95% ORR and 62% CR/sCR at a median follow-up of 10.3 months; additional patients with a more recent data cut will be presented during an oral presentation No delayed... Read More

Earned a $68M milestone payment from Kite for iMMagine-1 enrollment Submitted an abstract for the iMMagine-1 study at the 66 th ASH Annual Meeting The global Phase 3 trial, iMMagine-3, has been initiated by Kite U.S. FDA clears anito-cel IND application for myasthenia gravis, an autoimmune disease REDWOOD CITY, Calif. / Aug 08, 2024 / Business Wire / Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell... Read More

The companies share design of global Phase 3 trial, iMMagine-3; will evaluate anito-cel in patients exposed to both an immunomodulatory (lMiD) drug and an anti-CD38 monoclonal antibody Anito-cel will be manufactured from Kite’s Frederick, Maryland facility for iMMagine-3 as the successful technical transfer is complete Remain on track to present preliminary data from the iMMagine-1 trial by end of the year REDWOOD CITY,... Read More

REDWOOD CITY, Calif. / May 09, 2024 / Business Wire / Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights Cash, cash equivalents, and marketable... Read More

REDWOOD CITY, Calif. / May 07, 2024 / Business Wire / Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in two upcoming investor conferences: BofA Securities Health Care Conference 2024 (In Person) Presentation: Tuesday, May 14 at 3:40 p.m.... Read More

REDWOOD CITY, Calif. / Apr 04, 2024 / Business Wire / Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, at 12:45 p.m. ET. A live webcast of... Read More

REDWOOD CITY, Calif. / Mar 20, 2024 / Business Wire / Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26, at 1:00 p.m. ET. A live... Read More

REDWOOD CITY, Calif. , Feb. 29, 2024 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6 , at 2:50 p.m. ET . A live webcast of this... Read More

Expanded strategic partnership with Kite Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel (formerly CART-ddBCMA) in patients with relapsed or refractory multiple myeloma Ended the quarter with $729.2M , extending cash runway into 2027 REDWOOD CITY, Calif. , Feb. 28, 2024 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the... Read More

Median duration of response, progression free survival, and overall survival rate not reached with median follow-up after CART-ddBCMA (anito-cel) infusion of 26.5 months The estimated median progression free survival by Kaplan-Meier is 28 months Oral presentation at ASH will be on Monday, December 11, 2023 at 5 p.m. PT Company to host a live webcast event with an expert panel of clinicians on Monday, December 11 at 8 p.m.... Read More

Arcellx to receive $200M equity investment at $61.68 per share and an $85 million upfront cash payment Kite exercises option to Arcellx's ARC-SparX program ACLX-001 in multiple myeloma The companies expand the scope of their existing collaboration for CART-ddBCMA to include lymphomas REDWOOD CITY, Calif. and SANTA MONICA, Calif. , Nov. 15, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ:... Read More

Recently released ASH abstract for the company's Phase 1 CART-ddBCMA trial demonstrated that median duration of response, progression free survival, and overall survival not reached with median follow-up of 22 months after CART-ddBCMA infusion Company to present new patient data from its Phase 1 CART-ddBCMA trial during an oral presentation with a median follow-up of 26.5 months at the 65th ASH Annual Meeting in December... Read More

Abstract released today is from a June 2, 2023 data cut Median duration of response, progression free survival, and overall survival rate not reached with median follow-up after CART-ddBCMA infusion of 22 months A more recent data cut will be shared during the oral presentation with a median follow-up of 26.5 months Company to host a live webcast event with an expert panel of clinicians REDWOOD CITY, Calif. , Nov. 2, 2023... Read More

REDWOOD CITY, Calif. , Oct. 26, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that the management team will participate in two upcoming investor conferences: TD Cowen 7th Annual Fall Oncology Innovation Summit (Virtual) Fireside Chat: Friday,... Read More

Company expects to present preliminary data from iMMagine-1 study in 2H'24 REDWOOD CITY, Calif. , Aug. 14, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold placed on the... Read More

FDA has provided clearance to the company to continue dosing patients who have already undergone lymphodepletion REDWOOD CITY, Calif. , June 19, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, announced today that it has received notification from the U.S. Food and... Read More

REDWOOD CITY, Calif. , May 8, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported financial results for the first quarter ended March 31, 2023 . "Delivering our novel CAR-T therapy to multiple myeloma patients is at the heart of our mission," said Rami... Read More

REDWOOD CITY, Calif. , April 13, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference on Thursday, April 20, 2023 , at 1:00 p.m. ET.... Read More

Signed strategic collaboration with Kite to co-develop and co-commercialize late-stage clinical CART-ddBCMA in multiple myeloma Presented continued robust long-term responses from CART-ddBCMA Phase 1 expansion trial in patients with relapsed or refractory multiple myeloma Enrolled and dosed patients in pivotal iMMagine-1 clinical program for patients with rrMM Initiated ACLX-002 for patients with AML/MDS REDWOOD CITY, Calif.... Read More

REDWOOD CITY, Calif. , Feb. 21, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on Tuesday, February 28, 2023 , at 1:00 p.m. ET . A live webcast... Read More

REDWOOD CITY, Calif. , Feb. 2, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the company's participation in the following investor conferences: Guggenheim Oncology Conference 2023 Fireside chat on Thursday, February 9, 2023 , at 11:20 a.m. ET SVB... Read More

SANTA MONICA, Calif. & REDWOOD CITY, Calif.--( BUSINESS WIRE )--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced a global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need... Read More

100% ORR at both CART-ddBCMA dose levels; deep and durable responses observed in patients with poor prognostic factors 27 of 38 (71%) evaluable patients reached CR/sCR; 20 of 25 patients (80%) dosed > 12 months ago or had their 12-month follow-up visit by November 22, 2022 have reached CR/sCR No cases of Grade >3 CRS at RP2D and no delayed neurotoxicity or parkinsonian-like events First patients dosed in iMMagine-1 Phase 2... Read More

-- Collaboration leverages expertise across both companies, including Kite's global cell therapy leadership and industry leading reliable manufacturing -- -- Arcellx to receive $225M upfront payment; $100M equity investment; and up to $3.9B in total contingent consideration -- -- Companies to co-commercialize and split profits in the U.S.; Arcellx to receive low to mid-teen royalties outside the U.S. -- -- Arcellx to... Read More

Initiated iMMagine-1 Phase 2 pivotal study for CART-ddBCMA Longer-term follow-up patient data from the Phase 1 CART-ddBCMA expansion trial will be presented at the 64th ASH Annual Meeting in December Company to host a live webcast event with an expert panel of clinicians to discuss the clinical results on Sunday, December 11, 2022, at 11:00 AM CT REDWOOD CITY, Calif. , Nov. 14, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:... Read More

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14, 2022 , at 3:30 p.m. ET . A live webcast of the discussion will be accessible from... Read More

Completed upsized follow-on offering of common stock, raising $128.8 million in gross proceeds including full exercise of underwriters' option to purchase additional shares Presented continued robust long-term responses from its CART-ddBCMA Phase 1 expansion trial being evaluated in patients with r/r MM at the 2022 ASCO Annual Meeting Preclinical results from CART-ddBCMA published in Molecular Cancer Therapeutics Arcellx,... Read More